CymaBay Therapeutics Current Ratio 2013-2018 | CBAY

CymaBay Therapeutics current ratio from 2013 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CymaBay Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.20B $0.01B 14.83
2018-06-30 $0.22B $0.02B 12.81
2018-03-31 $0.23B $0.02B 12.90
2017-12-31 $0.10B $0.02B 6.35
2017-09-30 $0.10B $0.01B 7.39
2017-06-30 $0.02B $0.01B 1.49
2017-03-31 $0.03B $0.01B 2.28
2016-12-31 $0.02B $0.01B 1.99
2016-09-30 $0.02B $0.01B 3.16
2016-06-30 $0.03B $0.01B 4.00
2016-03-31 $0.04B $0.01B 5.41
2015-12-31 $0.04B $0.01B 6.88
2015-09-30 $0.05B $0.01B 7.89
2015-06-30 $0.03B $0.01B 3.31
2015-03-31 $0.03B $0.01B 2.52
2014-12-31 $0.04B $0.02B 1.82
2014-09-30 $0.04B $0.02B 2.95
2014-06-30 $0.03B $0.01B 1.85
2014-03-31 $0.03B $0.02B 1.99
2013-12-31 $0.03B $0.01B 3.40
2013-09-30 $0.03B $0.00B 14.32
2013-06-30 $0.00B $0.00B 0.00
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.00
2012-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.514B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.883B 8.74
Teva Pharmaceutical Industries (TEVA) Israel $19.341B 5.93
Mylan (MYL) United Kingdom $15.490B 6.38
Bausch Health Cos (BHC) Canada $8.272B 5.99
Dr Reddy's Laboratories (RDY) India $6.077B 24.24
Supernus Pharmaceuticals (SUPN) United States $1.860B 17.62
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.735B 2.89
Amphastar Pharmaceuticals (AMPH) United States $0.963B 104.50
Homology Medicines (FIXX) United States $0.897B 0.00
Assembly Biosciences (ASMB) United States $0.579B 0.00
Akorn (AKRX) United States $0.567B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.397B 0.00
Voyager Therapeutics (VYGR) United States $0.343B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.259B 0.00
Sol-Gel Technologies (SLGL) Israel $0.112B 0.00
Teligent (TLGT) United States $0.090B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.077B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Acasti Pharma (ACST) Canada $0.052B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Agile Therapeutics (AGRX) United States $0.028B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.006B 0.00